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High levels of osteoprotegerin are 
associated with coronary artery 
calcification in patients suspected 
of a chronic coronary syndrome
Mirthe Dekker1,2, Farahnaz Waissi1,2, Max J. M. Silvis3, Joelle V. Bennekom1, 
Arjan H. Schoneveld4, Robbert J. de Winter2, Ivana Isgum5, Nikolas Lessmann6, 
Birgitta K. Velthuis7, Gerard Pasterkamp8, Arend Mosterd9, Leo Timmers10 & 
Dominique P. V. de Kleijn1,11*
Plasma osteoprotegerin (OPG) and vascular smooth muscle cell (VSMC) derived extracellular 
vesicles (EVs) are important regulators in the process of vascular calcification (VC). In population 
studies, high levels of OPG are associated with events. In animal studies, however, high OPG levels 
result in reduction of VC. VSMC-derived EVs are assumed to be responsible for OPG transport and 
VC but this role has not been studied. For this, we investigated the association between OPG in 
plasma and circulating EVs with coronary artery calcium (CAC) as surrogate for VC in symptomatic 
patients. We retrospectively assessed 742 patients undergoing myocardial perfusion imaging 
(MPI). CAC scores were determined on the MPI-CT images using a previously developed automated 
algorithm. Levels of OPG were quantified in plasma and two EV-subpopulations (LDL and TEX), 
using an electrochemiluminescence immunoassay. Circulating levels of OPG were independently 
associated with CAC scores in plasma; OR 1.39 (95% CI 1.17–1.65), and both EV populations; EV-LDL; 
OR 1.51 (95% CI 1.27–1.80) and EV-TEX; OR 1.21 (95% CI 1.02–1.42). High levels of OPG in plasma 
were independently associated with CAC scores in this symptomatic patient cohort. High levels of 
EV-derived OPG showed the same positive association with CAC scores, suggesting that EV-derived 
OPG mirrors the same pathophysiological process as plasma OPG.
Osteoprotegerin (OPG) is a glycoprotein of the tumor necrosis factor receptor  family1,2. The main function of 
OPG is to inhibit osteogenesis by preventing the binding of the receptor activator of nuclear factor-κB ligand 
(RANKL) to its natural receptor activator nuclear factor-κB (RANK)3. The RANKL/RANK complex normally 
results in differentiation of osteoclasts and  osteogenesis3,4. OPG is therefore important in maintaining the bal-
ance between bone formation and  resorption5.
Additional to its function in bone metabolism, OPG is also implicated in cardiovascular diseases (CVDs)6. 
OPG is thought to be involved in the process of vascular calcification (VC). Experimental studies showed the 
presence of OPG within the vessel wall in the media and intima, and also in the fibrous cap of atherosclerotic 
 lesions7. Animal studies showed more VC in mice lacking OPG than mice without OPG-deficiency8,9. Further-
more, administration of OPG to atherosclerotic mice deficient for the LDL receptor led to less calcified plaques 
compared to the placebo  mice10. In contrast, human studies show that high levels of plasma OPG are associated 
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with a higher risk of future  events11,12. Although the exact role remains unclear, it might be that plasma OPG is 
produced as response to VC to protect against progression rather than preventing  it13,14.
The discrepancy between the presumed role of OPG in mice studies compared to large population studies 
could potentially be found in extracellular vesicles (EVs). EVs are bilayer lipid membranes containing bioactive 
content (nucleic acid, proteins and lipids)15. EVs are often referred to as “the liquid biopsy”, and considered as 
cell–cell  communicator16. Almost all cell types are able to produce  EVs16.
EVs derived from vascular smooth muscle cells (VSMCs) are thought to be involved in VC, and contain calci-
fication inhibitors such as OPG and matrix GLA-protein to regulate the micro-environment17,18. In pathological 
circumstances VSMC-derived EVs become microvascular calcified structures that form the start of advanced 
calcified plaques. In these calcified plaques OPG was found near these VSMC-derived EVs suggesting a role in 
transportation of OPG by EVs. EVs are often analyzed by total number of EVs, however their content might be 
also  informative19. We previously found that EVs can be separated based on size and density, potentially reflecting 
pathophysiological phenomenon. Despite OPG is associated with EVs, levels of plasma OPG and/or EV-derived 
OPG and its association with VC has not been studied.
Coronary artery calcium (CAC) score measured with coronary CT is used as surrogate for  VC20. The CAC 
score has been shown to be an excellent predictor of major adverse cardiovascular events (MACE), as well as a 
risk stratifying tool in patients suspected of chronic coronary syndrome (CCS)21–23.
The relationship between OPG and CAC is studied in asymptomatic population-based studies as well as 
patients with renal failure or diabetes  mellitus24–29. However, little is known about the association between CAC 
scores and levels of OPG in a symptomatic cohort. Neither do we know if OPG in circulating EVs provides 
additional information to plasma levels. In this study, we investigate the association between CAC, plasma OPG 
and circulating EV-derived OPG in two subsets of EVs in patients suspected of CCS.
Methods
Study cohort. We will perform a retrospective analysis on the prospectively collected MYOMARKER study 
cohort. The MYOMARKER (MYOcardial ischemia detection by circulation bioMARKERs) is a prospective sin-
gle center cohort study of consecutively enrolled patients who underwent myocardial perfusion imaging (MPI) 
with 82Rb-PET/CT because of chest pain suspected for CCS. All patients were aged > 18 years and included 
between August 2014 and September 2016 in the Meander Medical Center, the Netherlands. The study (NL5078) 
was approved by the Medical Ethics Committee-United (MEC U), in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from all patients, more details on the study protocol have been 
published  previously30. For the purpose of this study all patients with a history of a percutaneous coronary inter-
vention or coronary artery bypass grafting were excluded.
Study protocol. Levels of OPG were measured in previously collected blood samples. Venous blood was 
collected in EDTA tubes just before the MPI was performed. The samples were centrifuged 10 min at 1950×g at 
room temperature (RT) within 30 min after they were collected. After centrifugation all samples were aliquoted 
and directly stored at − 80 °C. Additional to the protein measurements CAC scores were obtained. For an over-
view of this study protocol see also Fig. 1.
Study protocol—extracellular vesicles isolation. Levels of OPG were measured in both plasma as well as in 
EVs. For this, two EV subpopulations were isolated. The isolation was performed as described in previous 
 publications30,31. In brief, a subset of EVs co-precipitate with low-density lipid particles (LDL) which allows 
separation. Magnetic beads were therefore added for both subpopulations  (nanomag®-D plain voor LDL and 
 nanomag®-D PET-OH for TEX). For the sequential isolation of the EV-LDL subpopulation Dextran Sulphate 
(DS, 0.05%, MP biomedicals) was used in combination with Manganese II Chloride (MnCl2, 0.05 M, Sigma-
Aldrich) (EV-TEX). The TEX subpopulation was precipitated with Xtractt buffer (1:4, Cavadis BV). Subse-
quently, a bio-plex handheld magnet was used. The remaining pellet containing the EV subpopulations was 
separated from magnetic bead debris with centrifugation, after removal lysis buffer was added to study the OPG 
levels carried within the EV subpopulations.
Study protocol—extracellular vesicle quantification. Levels of OPG were quantified in plasma and the EV-LDL 
and EV-TEX subpopulations using an electrochemiluminescence immunoassay (Meso Scale Discovery, MSD) 
following manufacturers protocol. In short; MSD GOLD Small Spot Streptavidine plates were coated O/N at 4 °C 
with OPG antibodies (MSD R-Plex human OPG antibody set, F21ZK). After washing three times with 150 µL 
wash buffer (0.2% Tween-20 in PBS) per well, the coated plates were blocked with blocking buffer A (MSD) for 
1 h at RT. Subsequently, plates were then washed as described before and 50 µL diluted plasma or protein lysate 
(twofold) from the EV subfractions, blancs or calibrators were added to designated wells and incubated for 2 h 
at RT. After washing the plates, detection antibody was added to all wells and incubated for 1 h. Plates were then 
washed and filled with 100 µL Reading Buffer (MSD) before analysis on the MSD Instrument (Quickplex SQ120, 
MSD). Protein concentration were measured as pg/mL. Data analysis was performed using MSD Discovery 
Workbench 4.0 software (Meso Scale Diagnostics).
Study protocol—extracellular vesicle characterization. Both the modified protocol which was used as well as 
extracellular vesicle characterization are described in detail in two previously published papers (specifically in 
the Supplemental Materials of Zhang et al.)32,33. Easy access to this data in a nice structured way can also be 
obtained via the EV-track that was created with EV-ID: EV200044.
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Study protocol—coronary artery calcium scoring. A previously developed algorithm was used to determine 
CAC scores on the low-dose, non-ECG-triggered, attenuation correction CT (LDACT) images acquired during 
 MPI34. Scans were acquired with 120 kVp on a hybrid scanner (Biograph CT Flow 64-Slice scanner, Siemens 
Healthcare, Knowxville, Tennessee). Detailed information on both the scanning protocol for MPI as well as CAC 
score measurements has been published  before30,35. In short, the developed algorithm first detects and excludes 
the lungs to identify the region of interest, on the LDACT. In the identified volume, the algorithm analyzes voxels 
above the standard intensity level threshold of 130 Hounsfield Units using two subsequent convolutional neural 
networks. The first network identifies candidate CAC voxels and assigns them a label of the coronary artery they 
reside in, while the second network identifies true CAC among the candidate CAC voxels. Finally, the identi-
fied CAC voxels are quantified using the per artery and total Agatston scores. As this method is not (yet) able 
to distinguish between CAC and a coronary stent, all patients with a history of coronary revascularization were 
excluded.
Statistical analysis. Continuous variables are summarized as mean ± standard deviation (SD) or median 
with interquartile range [IQR] depending on the distribution. Categorical variables are shown as number with 
corresponding frequencies. The distribution of all potential confounding  variables36, CAC scores, and biomark-
ers were assessed and transformation was performed achieve normal distributions. Levels of OPG were stand-
ardized after logarithmic transformation. Patients with levels of OPG > 3 SD were considered as influential outli-
ers and removed from the dataset.
Figure 1.  Study protocol. MPI myocardial perfusion imaging, CAC coronary artery calcification, MSD 
MesoScaleDiscovery platform. LDL and TEX refer to extracellular subfractions.
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For informative purpose and to correct for all possible confounders, associations between a wide range of 
cardiovascular risk factors and levels of OPG in plasma and both EV subpopulations were assessed. The con-
tinuous association between levels of OPG and the (logarithmically transformed) CAC score were assessed with 
Spearman’s correlation coefficient. Spearman’s correlation was used instead of Pearson since not all assumptions 
for Pearson’s correlation were met since no linearity and homoscedasticity was found between the variables. 
To assess this association in more detail we performed an ordered regression analysis between OPG levels and 
categories of CAC scores. For this CAC scores were divided in five commonly used categories: 0–9; 10–99; 
100–399; 400–999 and >  100026,37. Next to the univariable associations, adjusted ordered regression analysis 
were performed with two sets of confounders: (1) Age + sex and (2) a parsimonious set of variables. For this 
parsimonious set of variables we selected general cardiovascular risk factors and variables that were significantly 
associated with OPG in the regression analysis. The full set of variables contained: age, male sex, smoking, dia-
betes mellitus, hypercholesterolemia, a family history of CAD, known history of CAD, use of aspirin, statins or 
betablockade. After model reduction, using a stepwise backward method based on AIC this resulted in a final 
parsimonious model containing: age, male sex, hypertension, smoking, diabetes mellitus and a history of CAD. 
In addition, to assess if OPG in plasma and both EV subpopulation showed complementary information they 
were added all together in a final model.
To provide insight in the potential clinical use we investigated the discriminative ability of levels of OPG in 
plasma, EV-TEX and EV-LDL to detect significant CAC defined as a CAC score > 10 with logistic regression 
 analysis20. After internal validation with bootstrapping techniques C-statistics with corresponding confidence 
intervals were obtained. All analyses were performed with R Studio Version 1.1.456 (R Foundation for Statistical 
Computing, Vienna, Austria).
Results
In total 1265 patients were included in the MYOMARKER cohort study. Seventeen patients were incorrectly 
included in the study and therefore removed, another 500 patients were excluded because of a history of coronary 
revascularization, and in six patients there was not enough blood left to perform the analysis. This led to a study 
population of 742 patients (mean age 67 years, 50.5% male) who are the subject of this manuscript (Table 1). 
Many patients were overweight with a mean BMI of 27.6, 62% were known with hypertension and half of the 
patients suffered from hypercholesterolemia, and previous CVD was seen in 75.6%. With regards to medication 
use, aspirin, statins, betablockade and ACE- or angiotensin-II-inhibition was seen in nearly 50% of the patients. 
Supplemental Table 1 shows the distribution of cardiovascular risk factors between sexes, despite age (women 
tend to be slightly older in this study) no statistical differences were seen.
Table 1.  Baseline characteristics. Values are shown as mean ± SD or frequency with corresponding 




Age (years) 67 ± 10
Male sex (%) 375 (50.5)
BMI 27.6 (5.2)
Risk factors
Current smoking 145 (19.5)
Diabetes mellitus 139 (18.7)
Hypertension 460 (62)
Hypercholesterolemia 376 (50.7)
Familial coronary artery disease 179 (24.1)
Medical history
Cardiovascular disease 561 (75.6)
Coronary artery disease 53 (7.1)
Heart failure 37 (5.0)
Atrial fibrillation 119 (16.0)
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Association between OPG and cardiovascular risk factors. Bivariate correlations between levels of 
OPG in plasma and both EV-subpopulations and cardiovascular risk factors are provided in Table 2. In all three 
groups higher age, diabetes, hypertension and betablockade use were associated with higher levels of OPG, while 
male sex, and a family history of CAD were associated with lower levels of OPG. Hypertension was associated 
with higher OPG levels in plasma and the EV-LDL subpopulation.
Association between OPG and CAC . Valid CAC scores were derived in 720 patients. There were 184 
patients with no significant CAC < 10 (25.6%), 124 (17.2%) had mild CAC (10–99), 159 (22.1%) moderate (101–
399), 110 (15.2%) severe (> 400) and 143 (19.9%) had extensive CAC (> 1000). Supplemental Table 1 shows CAC 
scores were significantly higher in men compared to women. Across the OPG-plasma, LDL and TEX measure-
ments in total 15 measurements failed and were therefore reported as missing values. None of the values were 
considered as influential outliers. In Supplemental Table 2 the untransformed levels of OPG are summarized 
for each predefined category of CAC. In general levels of OPG gradually increased with increasing CAC scores. 
Supplemental Fig. 1 provides boxplots comparing levels of OPG for EV-LDL, EV-TEX and plasma between the 
different categories. No significant differences were found between moderate, severe and extensive CAC.
We assessed the associations between levels of OPG in plasma, EV-LDL and EV-TEX and CAC scores. 
Figure 2 shows that this association was significant for plasma and both EV-subpopulations, all with p values 
< 0.001. The strongest associations were found for EV-LDL with R: 0.3, and plasma, R: 0.29, compared to the 
weaker association for EV-TEX, R: 0.19.
More in depth analysis was performed with an ordered regression analysis to find associations between levels 
of OPG and categorical CAC scores, the results of this analysis can be found in Table 3. EV-LDL (odds ratio 
(OR) 1.81, 95% confidence interval (CI) 1.56–2.10), EV-TEX (OR 1.40; 95% CI 1.21–1.62) and plasma levels of 
OPG (OR 1.66; 95% CI 1.44–1.91) were significantly associated with categorical CAC scores. The associations 
remained significant after adjustment for only age and sex as well as full adjustment including cardiovascular 
risk factors (EV-LDL OR 1.51; 95% CI 1.28–1.80, EV-TEX OR 1.19; 95% CI 1.02–1.40 and plasma OPG OR 
1.38; 95% CI 1.16–1.63).
Discriminatory ability of OPG to detect significant CAC . To assess if OPG plasma levels and EV-
derived OPG levels provide additional information OPG levels in plasma and EVs were added together in the 
parsimonious model. In this model only EV-derived OPG in the LDL-subpopulation remained significantly 
associated with CAC (OR 1.18; 95% CI 1.05–1.17), while EV-derived OPG in the TEX subpopulation (OR 0.98; 
95% CI 0.79–1.21) and OPG plasma levels (OR1.18; 95% CI 0.93–1.52) were no longer significant predictors of 
CAC. To gain more insight in the potential discriminatory ability of OPG C-statistics were obtained (Table 4). 
Modest discrimination to predict presence of CAC (defined as CAC > 10) was seen for both plasma OPG and 
EV-LDL (C-statistics both 0.67), C-statistic for EV-TEX was lower with 0.63.
Discussion
In this study the association between levels of OPG in EVs and plasma were studied in a large symptomatic 
population suspected of CCS. We report three major findings, (1) we showed plasma levels of OPG as an inde-
pendent predictor of CAC scores in a symptomatic population (OR 1.39; 95% CI 1.17–1.65). (2) We reported 
the first data on EV-derived OPG and the relation with CAC. Additional to plasma OPG, high levels of both 
EV-LDL OPG (OR 1.51; 95% CI 1.27–1.80) as well as EV-TEX OPG (OR 1.21; 95% CI 1.02–1.42) were inde-
pendently associated with a higher CAC score category. (3) We assessed the clinical potential of plasma OPG, 
Table 2.  Bivariate correlations between OPG levels and cardiovascular risk predictors. All biomarkers were 
transformed depending on their original distribution and standardized. EV extracellular vesicle, EV-LDL and 
EV-TEX both different subpopulation of EVs, CAD coronary artery disease. Bold indicates p value < 0.05.
EV-LDL OPG EV-TEX OPG Plasma OPG
Beta p value Beta p value Beta p value
Variable
Age 0.05 < 0.001 0.03 < 0.001 0.05 < 0.001
Male sex − 0.32 < 0.001 − 0.26 < 0.001 − 0.33 < 0.001
Smoking − 0.07 0.42 0.03 0.70 0.01 0.88
Diabetes 0.26 < 0.01 0.32 < 0.001 0.44 < 0.001
Hypertension 0.22 < 0.01 0.10 0.14 0.22 < 0.01
Hypercholesterolemia 0.04 0.56 0.07 0.27 0.12 0.09
Familial CAD − 0.29 < 0.001 − 0.21 < 0.01 − 0.24 < 0.01
History of CAD 0.09 0.51 − 0.08 0.54 0.07 0.59
Ascal use 0.04 0.59 0.04 0.60 0.03 0.69
Statin use 0.14 0.04 0.01 0.89 0.10 0.16
Betablockade use 0.28 < 0.001 0.19 < 0.01 0.32 < 0.001
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and EV-derived OPG to correctly stratify patients to their corresponding CAC risk-category. The C-statistics to 
predict significant CAC (> 10) were only modest.
OPG and cardiovascular risk factors. We found a positive association between age and OPG, which 
was also observed in a substudy of the CLARICOR  trial38. Since atherosclerosis itself is highly age-dependent, 
the association between OPG and age might be explained by this. Higher levels of OPG are consistently found 
in women compared to men, the CLARICOR trial showed that women had, irrespective of diabetes or statin 
use 15% higher levels of OPG. A nested case–control study in the EPIC Norfolk trial showed higher levels of 
Figure 2.  Correlations between standardized levels of OPG and CAC scores in EV-LDL, EV-TEX and plasma 
CAC scores were logarithmically transformed. p values correspond to spearman’s coefficient.
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OPG in women compared to men for both cases (coronary event or death from coronary cause) and controls 
(healthy individuals)39. Both studies suggest biological difference in the levels of OPG between sexes but not 
directly in their association with disease, in our study we found the same result. Other associations with sex, 
diabetes, hypertension, family history with CAD and the use of beta blockade, were all consistent with existing 
 literature38,40. Interestingly, we did not find an association between statin use and OPG, whereas other studies 
 did38,41,42. The studies of Kadoglou et al.41 and Davenport et al.42 were both small studies involving different study 
populations compared to our study which might explain the difference. However, the CLARICOR trial was also 
a large study > 3000 participants and the percentage of patients on statin therapy was comparable to our study, 
approximately 40%. We have no clear explanation for this difference.
OPG and VC. We found OPG to be an independent predictor of CAC scores. This result is in agreement with 
previous studies showing the same association in the general  population28,29 as well as asymptomatic patients 
with established  CVD26,43–45. We now show that high levels of OPG are also associated with CAC in a sympto-
matic chest pain cohort. Additionally, we investigated the association of circulating EV-derived OPG with CAC 
for the first time. High levels of EV-derived OPG were also associated with high CAC scores, just as plasma levels 
of OPG. The positive association for both plasma OPG and circulating EV-derived OPG with CAC suggests that 
they probably both just mirror the same underlying  processes13,18,28. Two decades ago Jono et al. was the first to 
report that levels OPG were associated with the degree of CAD measured with coronary  angiography46. OPG 
was also found as predictor for progression of carotid  atherosclerosis13. Several animal studies also showed that 
in the absence of OPG more VC of the vessel wall is  seen8–10. Interestingly, Morony et al. showed that admin-
istration of OPG (and thus high levels of OPG) in mice deficient for the LDL receptor, led to less calcification 
of  plaques10. However, they did not find a decrease in number of plaques, nor lower cholesterol levels in these 
mice. This might indicate OPG could have a specific role in calcification of the plaques rather than preventing 
the atherosclerotic process itself. This finding is in contrast to the consistent finding of high levels of OPG in 
human and its association with MACE. Other groups have also suggested that high levels of OPG are a simple 
epiphenomenon of inflammation as result of  atherosclerosis47–49.
Previous studies showed VSMC derived EVs to be present in calcified plaques and they also showed OPG 
in these  EVs50. In normal physiological conditions VSMCs are contractile and secrete EVs that regulate the 
micro-environment which enable phenotypical  changes17. The secreted VSMC-derived EVs contain calcification 
inhibitors, such as OPG and matrix GLA-protein18. As a result of cellular stress and mineral imbalance VSMCs 
become less contractile and start to form calcified  EVs51. Calcified EVs tend to aggregate, form microcalcifica-
tion and increase calcification in existing  plaques52. In vulnerable plaques this could lead to rupture, whereas it 
could also further stabilize a calcified plaque under a thick fibrous  cap52. We did not find a different association 
between EV-derived OPG levels and CAC scores compared to plasma OPG. This suggests that EV-derived levels 
of OPG have a similar function as plasma OPG. The correlation between the EV-derived OPG levels and plasma 
OPG were statistically significant (LDL R: 0.75 P < 0.001 and TEX R: 0.66, P < 0.001) emphasizing this hypothesis 
(data not shown). Circulating EV-derived OPG represents a more general view of atherosclerosis itself rather 
than being involved in the actual process of VC like VSMC-derived EVs are.
Discriminatory ability of OPG. We showed a moderate correlation between levels of OPG and CAC, 
additionally, we assessed whether a single OPG measurement in plasma or EVs has the clinical potential to 
predict the presence of CAC scores (defined as CAC > 10). A cut-off value of 10 was used, since the aim of this 
Table 3.  Ordered regression analysis of OPG levels and categorical CAC scores. Full adjusted model included: 
age, sex, smoking, hypertension, diabetes mellitus and a previous history of coronary artery disease. Outcome 
variable was categorized in five classes: 0; 1–99; 100–399; 400–999 and > 1000. EV extracellular vesicle, EV-LDL 
and EV-TEX different subpopulations of EVs.
Univariable p value Age + sex adjusted p value Full adjusted p value
EV-LDL OPG 1.85 (1.60–2.15) < 0.001 1.60 (1.35–1.91) < 0.001 1.51 (1.27–1.80) < 0.001
EV-TEX OPG 1.42 (1.23–1.65) < 0.001 1.27 (1.08–1.49) < 0.001 1.21 (1.02–1.42) 0.024
Plasma OPG 1.69 (1.47–1.96) < 0.001 1.49 (1.27–1.77) < 0.001 1.39 (1.17–1.65) < 0.001
Table 4.  C-statistics for OPG to detect significant CAC. CAC > 10 refers to the clinical scenario with a binary 
outcome for the coronary artery calcium score defined as < 10 or > 10. EV extracellular vesicle, EV-LDL and 
EV-TEX different subpopulations of EVs.
CAC > 10
C statistic (95% CI)
EV-LDL OPG 0.67 (0.63–0.71)
EV-TEX OPG 0.63 (0.59–0.65)
Plasma OPG 0.67 (0.65–0.70)
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analysis was to see if OPG levels have potential to distinguish between patients at risk for future event (presence 
of CAC) and those without (CAC < 10). If so, this could have immediate clinical implications. After internal 
validation with bootstrapping techniques, we found a C-statistic to detect CAC > 10 for plasma OPG of 0.67, val-
ues for EV-derived OPG were comparable (EV-LDL: 0.67 and EV-TEX: 0.63). One other study investigated the 
discriminatory ability of a single OPG measurement to predict high CAC scores (> 400) in healthy  participants53. 
With C-statistics to detect CAC > 1, CAC > 10 and CAC > 400 of 0.5 they concluded OPG was not able to identify 
healthy participants with significant CAC scores. Although our C-statistics to detect CAC > 10 were also modest, 
the discriminatory ability of OPG was clearly better in symptomatic patients compared to healthy participants. 
To assess the added value of EV-derived OPG, we analyzed EV-OPG and plasma OPG together in the final par-
simonious model, no added value was observed. It is therefore likely that EV-derived OPG represents the same 
process as plasma derived OPG. The modest correlation as well as the cross-sectional, nature of this study makes 
it quite hard to determine the potential clinical importance of our findings. It remains to be elucidated what the 
exact role of OPG in the pathophysiology of vascular calcification is. For this, the etiologic relation should be 
studied in more detail and eventually a clinical impact study would be the next step.
Limitations. Several limitations merit consideration. Because of the retrospective character of the study, we 
were not able to investigate whether levels of OPG would have changed clinical decision making by the treat-
ing physician. The study remains limited to only one center, which might influence the generalizability of the 
results. In this study patients with previous coronary revascularization were excluded but the clinical relevance 
of CAC determination in these patients is limited anyway. Compared to general population studies the sample 
we studied is only modest (N = 742).
Conclusion
Increased levels of OPG in plasma were independently associated with CAC scores. High plasma OPG and EV-
OPG levels were associated with high CAC scores. Our findings suggests that plasma and EV-derived OPG seem 
to mirror the same underlying pathophysiological process.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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